期刊文献+

药物不良相互作用的临床调查与分析 被引量:4

在线阅读 下载PDF
导出
摘要 目的通过药物不良相互作用的临床调查,对产生药物不良相互作用的原因进行分析,指导临床医师合理、谨慎用药。方法采用回顾性调查方法,选取2005-2007年7个临床科室住院病历4500份,对其中9份病历中有重要临床意义的药物不良相互作用的表现及原因进行分析。结果老年、体弱、肝、肾功能减退或罹患多疾病者在数种药物联合治疗时,极易引起药物间不良作用。结论关注药物不良相互作用,特别是肝肾功能减退患者和老年患者用药时,临床医师应给予高度重视。
出处 《西北药学杂志》 CAS 2009年第5期414-416,共3页 Northwest Pharmaceutical Journal
  • 相关文献

参考文献8

  • 1朱金照,张捷,许其增,张志坚.乌司他丁治疗胰腺炎的疗效分析[J].临床消化病杂志,2002,14(4):153-155. 被引量:9
  • 2包志淑.头孢菌素类配伍氢化可的松致“双硫醒”反应2例[J].中国医院药学杂志,2008,28(6):504-504. 被引量:10
  • 3温文冰,成伙清,刘治军.他汀类药物与其他药物的相互作用[J].中国医院药学杂志,2008,28(4):298-301. 被引量:13
  • 4陈世铭.药物不良相互作用的临床意义与处理[M].3版.北京:中国科学技术出版社,2005:39-41,585-586,352-353.
  • 5Omoda K, Murakami T, Yumoto R, et al. Increassed erythrocyte distribution of valproic acid in pharmacokinetic interaction with carbapenem antibiotics in rat and human[J]. J Pharm Sci, 2005, 94(8): 1685-1693.
  • 6Hassan-Alin M, Andersson T, Nazi M, et al. Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects. Int J Clin Pharmacol Ther [J], 2006, 44(3): 119-127.
  • 7Saraya A, Yokokura M, Gonoi T, et al. Effects of fluoroquinolones on insulin secretion and β-cell ATP-sensitire K^+ channels [J]. Eur J Pharmacol, 2004, 497(1): 111-117.
  • 8Ishiwata Y, Sanada Y, Yasuhara M. Effects of gatifloxacin on serum glucose concentration in normal and diabetic rats [J]. Biol Pharm Bull, 2006, 29(3): 527-531.

二级参考文献34

  • 1陈新谦,金有豫,汤光.新编药物学[M].15版.北京:人民卫生出版社.2004:38.
  • 2Shitara Y, Hirano M, Sato H, et al. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin., analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil[J]. J Pharmacol Exp Ther, 2004, 311 (1) : 228-236.
  • 3Christians U,Jacobsen W,Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reduetase inhibitors in transplant patients:are the statins mechanistically similar[J]. Pharmacol Ther, 1998,80(1 ):1-34.
  • 4Cohen LH,van Leeuwen RE,van Thiel, et al. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes [J]. Biopharm Drug Dispos,2000,21 (9) : 353-364.
  • 5Fujino H,Saito T,Tsunenari Y, et al. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors[J]. Xenobiotica,2004,34(11-12):961-971.
  • 6Andrus MR. Oral anticoagulant drug interactions with statins:case report of fluvastatin and review of the literature[J]. Pharmacotherapy, 2004,24(2): 285-290.
  • 7Ahmad SL. Warfarin interaction[J]. Arch Intern Med, 1990, 150(11) :2407.
  • 8Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors[J]. Am J Cardiol,2004, 94(9) : 1140-1146.
  • 9Kanathur N, Mathai MG, Byrd RP Jr, et al. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis [J]. Tenn-Med,2001, 94(9): 339-341.
  • 10Lewin JJ, Nappi JM, Taylor MH . Rhabdomyolysis with concurrent atorvastatin and diltiazem [J]. Ann Pharmacother, 2002, 36(10): 1546-1549.

共引文献29

同被引文献30

引证文献4

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部